CompletedPhase 1NCT00085358
Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)
Studying Malignant mixed Müllerian tumor of the ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Joan WalkerGynecologic Oncology Group
- Intervention
- carboplatin(drug)
- Enrollment
- 40 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2004
Study locations (16)
- University of California Medical Center At Irvine-Orange Campus, Orange, California, United States
- Colorado Gynecologic Oncology Group, Aurora, Colorado, United States
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
- University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
- Greater Baltimore Medical Center, Baltimore, Maryland, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Cooper Hospital University Medical Center, Camden, New Jersey, United States
- Case Western Reserve University, Cleveland, Ohio, United States
- Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, United States
- Lake University Ireland Cancer Center, Mentor, Ohio, United States
- University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
- Cancer Care Associates-Midtown, Tulsa, Oklahoma, United States
- Cancer Care Associates-Yale, Tulsa, Oklahoma, United States
- Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
- +1 more locations on ClinicalTrials.gov
Collaborators
Gynecologic Oncology Group
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00085358 on ClinicalTrials.govOther trials for Malignant mixed Müllerian tumor of the ovary
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06483048MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian CancerMayo Clinic
- RECRUITINGPHASE2, PHASE3NCT03651206Recurrent Ovarian CarcinoSarcoma Anti-pd-1 NiraparibARCAGY/ GINECO GROUP
See all trials for Malignant mixed Müllerian tumor of the ovary →